01 TYPICAL PAIR-FIRST SEARCH
“Do Drug A and Drug B work better together?”
Often focused on predicted or measured joint activity under a specified exposure and disease context.
Important question. Incomplete starting point.
ONCOLOGY DISCOVERY · PATENT PENDING
Beyond drug synergy.
Discover what treatment changes in a tumor.
Most combination searches begin with two drugs. TSRIP begins with a different question: What biological state does a treatment leave behind—and which intervention might exploit it?
Our research framework connects treatment history, causal biology, residual vulnerabilities, therapeutic architectures and decision-changing experiments. Potential opportunities may involve drugs, cell-based agents, sequencing or delivery approaches that conventional pairing methods overlook.
For scientific research and development—not clinical treatment recommendations.
TUMOR-STATE RESEARCH LOGIC01 / DISCOVERY
01Baseline tumor stateBiological context + treatment history
Therapeutic intervention ↓
02Post-treatment stateDo not assume a single cause
◈SelectedPre-existing survival
⌁InducedAdaptive response
◌ExposureDelivery limitation
↓
EVIDENCE-CONDITIONED OPPORTUNITIES
New targetsSequencingImmune cellsDelivery
✓ Potential opportunities requiring experimental validation
Illustrative conceptual framework; not a computational output or empirical dataset.
OUR DISCOVERY PRINCIPLE
Treatment does not simply suppress disease. It can select, induce or reveal a new biological state.
↘
THE DISTINCTIVE QUESTION
A different starting point
changes what you can find.
Drug synergy is valuable, but it is not the whole discovery problem. A treatment may change the biology, timing, or location of what remains. Those changes can open research directions that are invisible in a static drug-pair comparison.
02 TSRIP · STATE-FIRST DISCOVERY
“What did Drug A change—and what becomes vulnerable next?”
Examines treatment-selected and treatment-induced states, causal escape, residual function, exposure, timing and location before proposing next interventions.
✳ Concurrent synergy remains one option—not the only answer.
THE RESEARCH FRAMEWORK
From tumor-state change
to a falsifiable research plan.
A six-stage, evidence-traceable workflow. Different scientific functions can be evaluated independently and brought together under governed research logic.
Define the tumor state
Represent the biological context, treatment history and relevant baseline, residual or post-intervention states.
Context before candidatesTrace causal change
Map upstream triggers, downstream effects, bypass mechanisms and the timing of observed changes.
Direction · time · uncertaintyFind residual liabilities
Explore overlooked functions, unaddressed mechanisms, resistance paths and orthogonal dependencies.
Discovery beyond pairingCompare intervention designs
Evaluate simultaneous, sequential, staged and delivery-modified options, including cell-based modalities and formulation concepts where appropriate.
Biology ≠ feasibilityChallenge the proposed mechanism
Surface conflicting findings, missing evidence, alternative causes, safety and feasibility constraints.
Evidence-based no-go gatesSpecify decisive experiments
Produce ranked research options and potential laboratory comparison plans, controls and falsification tests for human review.
Research blueprint, not a claim of validationWHY THE DISTINCTION MATTERS
One treatment.
Multiple possible explanations.
Different next experiments.
A post-treatment tumor can appear resistant for very different reasons. The research path should change with the causal explanation—not rely on a single “resistance” label.
Illustrative reasoning paths only. No patient data, efficacy prediction or actual TSRIP-generated analysis is shown.
STATE-TO-OPPORTUNITY EXPLORERSELECT A POSSIBLE STATE
01 / INTERPRETATION
Pre-existing cell populations may have survived treatment.
02 / CRITICAL QUESTION
Did treatment enrich a population that was already present before exposure?
03 / DISCRIMINATING EVIDENCE
Compare matched baseline and post-treatment cell-state or clonal evidence; distinguish selection from newly induced signaling.
04 / RESEARCH DIRECTION
Orthogonal vulnerabilitySequence comparison
✓ Evidence first · Alternatives retained · Human review required
FROM SCIENCE TO RESEARCH ACTION
Broader opportunities.
Sharper next steps.
TSRIP is designed to move beyond ranking predicted drug pairs toward research decisions that can be examined, challenged and transferred into experimental programs.
History-aware sequencing
Compare A then B, B then A, concurrent treatment or staged intervention based on the state each may create—not simply later-line eligibility.
Unanticipated mechanisms
Investigate upstream triggers, feedback, parallel survival programs, immune or stromal remodeling and spatial vulnerabilities.
Architecture & delivery
Examine separate dosing, co-formulation, carriers, cell-based interventions or alternative delivery through modality-specific feasibility and safety gates.
Experiment-ready reasoning
Translate candidate mechanisms into comparisons, controls, readouts and decision-changing laboratory questions—without claiming studies have been run.
BEYOND SMALL MOLECULES
The next intervention may be a living cell.
TSRIP is designed to evaluate potential opportunities involving immune-cell therapeutics when a treatment-altered tumor state creates a scientifically supported opening. Candidate modalities can be considered alone, in combination or in a defined sequence with other interventions.
Natural killer (NK) cells
Explore tumor states with altered immune recognition, stress signaling or susceptibility to innate cytotoxicity, subject to receptor–ligand, trafficking and inhibitory-context evidence.
CD8+ T cells
Assess potential cytotoxic T-cell approaches against residual disease, with attention to antigen presentation, HLA context, functional exhaustion and access to tumor tissue.
Macrophage-based agents
Investigate opportunities involving phagocytosis and myeloid-state remodeling where the tumor microenvironment, cell phenotype and safety profile support further evaluation.
Gamma delta (γδ) T cells
Examine tumor stress states and recognition pathways that may provide opportunities for γδ T-cell interventions, including tissue access and suppressive microenvironment factors.
Different cells. Different mechanisms. Different evidence requirements.
Discuss a cell-based research question
Each potential opportunity is assessed against the specific tumor state, treatment sequence, relevant biological evidence and modality-specific feasibility—not an assumption that every immune-cell approach will work in every tumor.
BUILT FOR SCIENTIFIC SCRUTINY
Good discovery must also know
what it does not know.
The framework distinguishes evidence from inference. A plausible mechanism is not proof of synergy, safety, manufacturability or clinical benefit.
01
Source traceability — capture which findings support a proposed causal relationship.
02
Competing explanations — distinguish induced adaptation, selection and delivery failure.
03
Negative evidence — retain contradictions, uncertainty and rejected options.
04
Experimental gates — identify the smallest comparison that could meaningfully change a decision.
05
Human governance — treat outputs as potential research opportunities pending expert review and validation.
FOR PHARMA & BIOTECH R&D
A research mandate, not
a generic prediction feed.
Shape the inquiry around your assets, mechanisms, tumor states and evidence requirements. TSRIP can be scoped for a single question or for recurring exploration under agreed scientific and operational boundaries.
Asset-focused discovery
Explore how one therapeutic intervention changes tumor biology, and which potential drug, immune-cell or other next interventions deserve testing.
Defined asset · Defined question
Standing research mandates
Set priority tumor states or therapeutic mechanisms for recurring, evidence-updated opportunity evaluations.
Sponsor-directed · Periodic review
Bounded exploratory programs
Investigate connected research opportunities across interventions within agreed scope, evidence thresholds and review gates.
Bounded search · Human oversight
Engagement configurations are illustrative and subject to project scoping. They are not representations of currently completed research studies or guaranteed platform services.
START WITH YOUR SCIENTIFIC QUESTION
What might your treatment
make possible next?
For pharmaceutical discovery, translational research, oncology innovation and research collaboration conversations.
SCIENTIFIC & PARTNERSHIP INQUIRIESdiscover@tsrip.ai
Tell us the asset or tumor-state problem you want to explore. We can discuss an appropriately scoped research evaluation.
Request a discussion